Nantes, October 13, 2025
Nantes-based biotech company XENOTHERA is accelerating its developments in oncology with several multispecific glyco humanized antibody (GH-pAb) programs. The company today announced new clinical milestones and major publications in international journals and conferences.
Clinical advances for XON7 in solid tumors
The XON7 program is developing a GH-pAb antibody targeting a unique combination of tumor antigens expressed in several solid cancers. The clinical trial, conducted in France and Belgium since late 2023 (FIPO trial, NCT06154291), is supported by BPI France.
In September 2025, the scientific committee approved the start of a backfilling phase at a dose of 16 mg, based on pharmacokinetic data obtained from patients.
The most recent results will be presented at the ESMO 2025 congress in Berlin (poster 984B, October 19, 12:00 p.m.–12:45 p.m.).
LIS22: positive signals in peripheral T-cell lymphomas
The LIS22 program, dedicated to peripheral T-cell lymphoma (PTCL) – a serious disease with high unmet medical need – has been in clinic in France and Italy since mid-2024 (PALT trial, NCT06495723), with funding from France 2030 i-DEMO program.
The scientific advisory board has recently approved the move to a 7.5 mg dose, highlighting the candidate’s lack of toxicity and therapeutic potential.
LIS22 was the subject of an oral presentation and an abstract published in the proceedings of the ICML 2025 world congress in Lugano (International Conference on Malignant Lymphoma).
International publication for XON9 in hepatocellular carcinoma
The XON9 program explores the therapeutic potential of a new GH-pAb antibody targeting hepatocellular carcinoma.
The results have just been published in the special edition on hepatology of the International Journal of Molecular Sciences (IJMS).
The article, entitled “XON9 – A Glyco-Humanized Polyclonal Antibody Effective Against Hepatocellular Carcinoma” (Royer et al.), describes the in vitro and in vivo data and demonstrates the superiority of XON9 over Sorafenib, the current standard of care for this cancer.
These results reinforce XENOTHERA’s strategy of developing a new generation of multispecific antibodies to address unmet needs in oncology.
“We are delighted to be advancing science for the benefit of patients and confirming the value of our first-in-class technology in serious cancers. The multispecific and multimodal approach represents a tremendous innovation, and we believe that the future will confirm its value for patients. These results already confirm XENOTHERA’s credibility in the field of oncology. I would like to congratulate our teams on these magnificent advances and thank the patients and investigators for their commitment to these trials.” — Dr. Odile Duvaux, President of XENOTHERA
About XENOTHERA:
Founded in 2014 by a team of renowned European scientists (Professors Soulillou, Bach, Cozzi, and Galli in France and Italy) and chaired by Odile Duvaux, MD, PhD, graduate of the École Normale Supérieure, XENOTHERA is a biotechnology company based in Nantes that develops new therapeutic approaches in several fields, including transplantation, oncology, and immunology, based on a unique glyco-humanized antibody (GH- pAb) technology. Its technological platform is based on dual expertise in genetics and immunology. The biotech company has a portfolio of products, three of which are currently in clinical trials. Its main programs are LIS1 in transplantation, XON7 in solid tumors, and LIS22 in oncohematology.
XENOTHERA is part of the scientific, economic, and medical ecosystem of the Pays de la Loire region (France). Since its creation, the company has raised €43 million, with its main financiers being the Pays de la Loire Region, BPI France, and the European EIC Fund, as well as private investors. XENOTHERA is a France 2030 winner.
More information: www.xenothera.com
Follow XENOTHERA on social media: LinkedIn , X
Relations médias :
Akkanto
Carmen Borissova
+33(0)06 09 91 33 03
carmen.borissova@akkanto.fr / xenothera@akkanto.fr